DBV Technologies (DBVT) trades at a ~$1B market cap, but Viaskin faces a shrinking peanut allergy market and formidable competition, warranting caution. Viaskin’s addressable market is materially ...
Châtillon, France, July 14, 2026DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026Company to ...
Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and Business Update Conference Call. All participants will be in listen-only mode. [Operator ...
DBV is developing a patch treatment for peanut allergies called Viaskin Peanut, and on Wednesday, it published an update about the clinical testing of this product. DBV said that the results of the ...
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq ...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...
In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 ...
DBV Technologies SA shares soared after the company said its experimental skin patch helped young children with a peanut allergy in a crucial study. The product, called Viaskin, showed it could help ...
DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in ...
Châtillon, France, June 29, 2026DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results